Evotec stock narrows Q3 EBITDA loss as 2026 outlook holds

Evotec reported a mixed set of third-quarter and nine-month results on Thursday, November 5, 2026, with quarterly profitability improving sharply while year-to-date revenue remained below the prior-year level. In a release carried by finanzen.net, the company said its third-quarter revenue was broadly stable and its adjusted EBITDA loss narrowed significantly from a year earlier.

Evotec stock traded at 3.10 euros on Lang & Schwarz at 11:43 CET on Friday, November 6, 2026, 0.32 percent above the Xetra close of Thursday, November 5. The quote was 3.33 percent above the Lang & Schwarz previous close of 3.00 euros.

Investors can follow the real-time quote of Evotec stock.

Quarterly profitability improves

Group revenue in the third quarter reached 164.9 million euros, compared with 163.9 million euros in the same period of 2025. At constant exchange rates, revenue was 164.2 million euros. Adjusted Group EBITDA improved to a loss of 1.6 million euros from a loss of 15.0 million euros a year earlier, an 89.1 percent improvement that Evotec primarily attributed to lower cost of revenue.

The two operating divisions both contributed to the quarterly improvement. Discovery and Preclinical Development revenue declined modestly year on year, while its adjusted EBITDA loss narrowed. Just - Evotec Biologics increased quarterly revenue and reduced its adjusted EBITDA loss compared with the prior-year period.

Nine-month pressure remains

For the first nine months through September 30, Group revenue fell to 465.0 million euros from 535.1 million euros in the prior-year period. Evotec attributed the decline in Discovery and Preclinical Development mainly to lower sales-to-revenue conversion. Just - Evotec Biologics also faced a comparison affected by a 25 million US dollar Sandoz license sale recognized in the first quarter of 2025 and delayed program activities.

Adjusted Group EBITDA for the nine-month period was a loss of 44.3 million euros, compared with a loss of 16.9 million euros in the prior-year period. Research and development expenses fell to 29.7 million euros from 42.3 million euros, or 6.4 percent of revenue versus 7.9 percent previously. Evotec ended the quarter with liquidity of 400.9 million euros and a net debt position.

Guidance and longer-term targets

Evotec reaffirmed its 2026 guidance for Group revenue of 570 million to 610 million euros on a reported basis and adjusted EBITDA of negative 105 million to negative 70 million euros. At constant exchange rates, the ranges are 595 million to 635 million euros for revenue and negative 90 million to negative 60 million euros for adjusted EBITDA. Management expects both measures to finish toward the upper ends of their ranges, while cautioning that quarterly performance can vary.

The company also presented a 2030 framework targeting around 1 billion euros in Group revenue, with further upside potential. Evotec aims for an adjusted EBITDA margin of 20 percent by the end of 2028 and above 20 percent by the end of 2030. The framework assigns roughly 40 percent of 2030 revenue to the Discovery and Preclinical Development base business, about 20 percent to partnerships and innovation activities, and about 40 percent to Just - Evotec Biologics.

Evotec said its Horizon transformation was ahead of plan, with more than 20 percent of the 75 million euro annual run-rate savings target delivered by the end of September. The company also confirmed the selection of Just - Evotec Biologics by Vertex Pharmaceuticals for commercial manufacturing of povetacicept and highlighted new research collaborations and clinical progress across its platforms.

The DAX provides the broader German equity-market context for Evotec stock through current market coverage.

Further results commentary and company developments are available in More news and analyses on Evotec stock.